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reduced diastolic blood pressure (r=–0.55; p=0.01). In the non diabetic group,
tHcy levels were negatively correlated with HTase activities (r=0.75; p=0.00)
and diet score (r=–0.70; p=0.01) while HTase activities were positively corre-
lated with diet score (r= 0.75; p= 0.00). 
Conclusion: Elevated homocysteine in diabetic patients may partly be
explained by the diminished HTase and could be considered as an additional
risk factor for cardiovascular events. Adherence to Mediterranean diet could
be the first efficient step to prevent these complications.
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Aims. Coronary artery bypass grafting is conventionally considered the
standard treatment for significant left main coronary artery (LMCA) disease.
The management of severe coronary artery disease in the octogenarians is still
highly debated. The aim of this study was to appreciate safety and effective-
ness of percutaneaous coronary intervention (PCI) in octogenarians who were
denied by the heart team for surgical revascularization.
Methods and Results. The study included 70 consecutive patients
80 years of age who had undergone PCI for the treatment of LMCA and
who were primary denied by our center’s heart team for surgical revascular-
ization. In our study mean age was 83.4 ± 2.6 years [range 80-89]. Mean
Euroscore was 21.1 ± 16.7 and mean Syntax score was 28.6 ± 8.7. Ten (14%)
were treated with LMCA PCI in the context of ST-segment Elevation Myo-
cardial Infarction (STEMI). Overall in-hospital mortality was 11%. There
were two cases of fatal stent thrombosis at 2 and 7 days respectively after
DES implantation. Mean follow-up time was 27.2 ± 24.9 months [range 4-80
months]. Overall mortality at the end of follow-up was 28%. Cardiac death
was found in 18 patients and 2 patients died from terminal renal insufficiency.
2 other patients (3%) presented with a new STEMI, 7 (10%) with a new non-
STEMI, 13 (19%) with heart failure and 2 (3%) had minor hemorrhage. There
was a percutaneous target vessel revascularization in 7 (10%) patients. During
follow-up, the total major adverse cerebral and cardiovascular event
(MACCE) was 48.5%. Distal LMCA disease and male sex were independent
factors predicting mortality (p<0.05). 
Conclusions. Stent implantation was technically feasible and relatively
safely applied for the treatment of LMCA disease in octogenarian who were
refused for surgery and who represented a high risk population for PCI and
coronary events. Despite a high rate of MACCE, the clinical long term out-
come seems good for this specific population with heavy basal status.
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Background: Reduced concentrations of clopidogrel active metabolite
have been associated with diminished platelet inhibition and higher rates of
adverse cardiovascular events. Paraoxonase-1 (PON1) has recently been pro-
posed as a key enzyme for clopidogrel metabolic activation. We tested the
effects of PON1 polymorphisms on clopidogrel pharmacokinetics (PK) and
pharmacodynamics (PD), and the occurrence of cardiovascular outcomes in
young post-MI patients treated with clopidogrel.
Methods and Results: We genotyped PON1 (Q192R and L55M) and
CYP2C19 variants in 106 patients enrolled in the PK/PD CLOVIS-2 trial.
Patients were randomly exposed to 300mg or 900mg clopidogrel loading dose
in a cross-over study design. Clopidogrel active metabolite isomer H4 (clopi-
H4) and platelet function testing were measured serially post-loading dose.
There was no significant association between PON1 Q192R or L55M and
clopi-H4 formation or antiplatelet response to clopidogrel following either
loading dose. Using multivariable linear regression analyses, the CYP2C19*2
allele was the only predictor of clopi-H4 generation and platelet response irre-
spective of the platelet function assay. CYP2C19 loss-of-function but not
PON1 variants were significantly associated with increased risk of major car-
diovascular events (death, myocardial infarction and urgent coronary revascu-
larization) occurring during long-term clopidogrel exposure in 371 young
post-MI patients (<45 years) enrolled in the AFIJI cohort: CYP2C19 loss-of-
function allele carrier vs non carrier, HR 2.26 95%CI [1.15-4.41], p=0.02;
PON1 QQ192 vs QR/RR192, HR 1.03 95%CI [0.50-2.11], p=0.93; PON1
MM55 vs ML/LL55, HR 1.52 95%CI [0.75-3.08], p=0.24. 
Conclusion: Our study does not confirm that PON1 Q192R or L55M can
influence clopidogrel PK or PD in post-MI patients.
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Aims: To assess ability of different magnitocardiogtaphic (MCG) indices
to discriminate between ischemic changes of electrophysiologic properties of
myocardium early after STE AMI and non-ischemic changes.
Methods: 32 pts with STE AMI (21 pts with ischemia on stress test – 1st
group and 11 pts without ischemia – 2nd group examined on 7-10th day after
STE AMI) , 32 pts with myocarditis (3rd group) and 34 healthy (4th group)
were evaluated . All patients had neither conduction abnormalities, ischemic
changes on resting ECG, nor LV hypertrophy, systolic dysfunction on
EchoCG. Healthy and AMI pts had exercise test on the same day with MCG.
Averaged deviations of largest vectors of current density distributions (CDD)
on ST slope starting at 60 ms from J to Tapex (first half of this ST portion –
D1, second half – D2), second portion of Ta-Te (D4) and differences in direc-
tions of vectors of CDD on R and Tapex (delta RTa), ratios between global
CDD on peak R to that on Tapex (GCDD-RTa) were assessed.
Results: In 1st, 2nd, 3rd and 4th groups median D1 were 9.0, 5.0 ,3.0, and
2.25 grads respectively, p<0.05; median D2 were 11.9, 5.3 , 3.5, and 1.60
grads, p<0.01; D4 were 12.3, 6.3 , 7.3, and 5.0 grads, p<0.05; median delta
RTa were 47.0, 32.5, 22.5 and 12.5 grads respectively, p<0,01. Best sensitivity
(91%) and specificity (71% and 76%) in discerning patients with and without
ischemia after MI were D2> 8.1 and delta RT >69.5 grads. 
Of parameters consistent with myocarditis was ratio GCDD-RTa (In 1st,
2nd, 3rd and 4th groups median GCDD-RTa 3.24, 4.01, 7.13 and 5.0 respec-
tively, p<0,01 between 3rd group and other study groups) which did not differ
significantly in STEMI patients. 
Conclusion: MCG is informative for assessment of patients with and
without coronary artery disease. MCG is capable of detection changes in elec-
trophysiologic properties in myocardium susceptible to ischemia and may be
used to select patients with STE MI who need revascularization. 
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Background: Bleeding is a major complication in patients treated for acute
coronary syndromes (ACS) with antithrombotic and invasive therapies. Con-
sequently, the benefit of such therapies should be balanced against the poten-
tial risk of hemorrhagic complications. CRUSADE and more recently
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